Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway
Fig 2
Enhanced cell growth inhibition by combination treatment of VK2 and VEN in AML cell lines.
(A-E) AML cell lines (HL-60, SKM-1, THP-1, U-937, and MOLM-14) were treated with VK2 in the presence or absence of VEN at indicated concentrations for 48 h and 72 h. Upper: The viable cell number was assessed by CellTiter Blue assay. Data are presented as the mean ± SD. *p<0.05 vs. VEN 0 nM. Lower: The synergistic effect of VK2 and VEN combined treatment on AML cell proliferative inhibition was statistically analyzed using Combenefit software. Mapping of the synergy levels on the experimental combination dose-response surface. A higher score shown in denser blue indicates a stronger synergistic effect. n = 3.